The active metabolite of prasugrel, R-138727, improves cerebral blood flow and reduces cerebral infarction and neurologic deficits in a non-human primate model of acute ischaemic stroke
Atsuhiro Sugidachi(Daiichi Sankyo (United Kingdom)), Atsuyuki Tomizawa(Daiichi-Sankyo (Japan)), Makoto Mizuno(The University of Tokyo), Kousaku Ohno(Sanin Rosai Hospital), Joseph A. Jakubowski(Indiana Biosciences Research Institute)
Cited by 14
Related Papers
Prasugrel Compared With High Loading- and Maintenance-Dose Clopidogrel in Patients With Planned Percutaneous Coronary Intervention
|Circulation|2007|882
Pretreatment with Prasugrel in Non–ST-Segment Elevation Acute Coronary Syndromes
|New England Journal of Medicine|2013|651
A Randomized Trial of Prasugrel Versus Clopidogrel in Patients With High Platelet Reactivity on Clopidogrel After Elective Percutaneous Coronary Intervention With Implantation of Drug-Eluting Stents
|Journal of the American College of Cardiology|2012|617